L A Magee

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. ncbi request reprint Variations in early and intermediate neonatal outcomes for inborn infants admitted to a Canadian NICU and born of hypertensive pregnancies
    Megan A Hayter
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC
    J Obstet Gynaecol Can 27:25-32. 2005
  2. pmc Protecting intellectual property associated with Canadian academic clinical trials--approaches and impact
    Sue Ross
    Department of Obstetrics and Gynaecology, University of Calgary, 1441 29th Street NW, Calgary, T2N 4J8, Canada
    Trials 13:243. 2012
  3. doi request reprint Prevention and treatment of postpartum hypertension
    Laura Magee
    Departments of Internal Medicine UBC and Specialized Women s Health BC Women s Hospital, British Columbia Women sHospital and Health Centre, Vancouver, Canada
    Cochrane Database Syst Rev 4:CD004351. 2013
  4. pmc Ethics review as a component of institutional approval for a multicentre continuous quality improvement project: the investigator's perspective
    Hanna Ezzat
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, V6 H 3N1, Canada
    BMC Health Serv Res 10:223. 2010
  5. ncbi request reprint The Control of Hypertension In Pregnancy Study pilot trial
    L A Magee
    Department of Medicine, University of British Columbia, Vancouver, Canada
    BJOG 114:770, e13-20. 2007
  6. ncbi request reprint Women's views of their experiences in the CHIPS (Control of Hypertension in Pregnancy Study) Pilot Trial
    L A Magee
    Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Hypertens Pregnancy 26:371-87. 2007
  7. doi request reprint The management of severe hypertension
    Laura A Magee
    Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Semin Perinatol 33:138-42. 2009
  8. ncbi request reprint The safety of antihypertensives for treatment of pregnancy hypertension
    L A Magee
    Department of Specialized Women s Health, BC Women s Hospital and Health Centre, 4500 Oak Street, Room IU59, Vancouver, BCV6H 3N1, Canada
    Expert Opin Drug Saf 3:25-38. 2004
  9. ncbi request reprint Control of hypertension in pregnancy
    Laura A Magee
    BC Women s Hospital and Health Centre and the Child and Family Research Institute, University of British Columbia, 4500 Oak Street, Room D213, Vancouver, BC V6H 3N1, Canada
    Curr Hypertens Rep 11:429-36. 2009
  10. pmc Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis
    Laura A Magee
    University of British Columbia, BC Women s Hospital and Health Centre, 4500 Oak Street, Vancouver, BC, Canada V6H 3N1
    BMJ 327:955-60. 2003

Detail Information

Publications53

  1. ncbi request reprint Variations in early and intermediate neonatal outcomes for inborn infants admitted to a Canadian NICU and born of hypertensive pregnancies
    Megan A Hayter
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC
    J Obstet Gynaecol Can 27:25-32. 2005
    ..To determine whether neonatal intensive care unit (NICU) outcomes vary by centre for inborn neonates of hypertensive pregnancies and, if so, whether that variation might be related to between-centre variations in obstetric practice...
  2. pmc Protecting intellectual property associated with Canadian academic clinical trials--approaches and impact
    Sue Ross
    Department of Obstetrics and Gynaecology, University of Calgary, 1441 29th Street NW, Calgary, T2N 4J8, Canada
    Trials 13:243. 2012
    ..Funding agencies should formalize rules around open versus restricted access to the study protocol just as they have around open access to results...
  3. doi request reprint Prevention and treatment of postpartum hypertension
    Laura Magee
    Departments of Internal Medicine UBC and Specialized Women s Health BC Women s Hospital, British Columbia Women sHospital and Health Centre, Vancouver, Canada
    Cochrane Database Syst Rev 4:CD004351. 2013
    ..A significant rise in BP may be dangerous (e.g., can lead to stroke), but there is little information about how to prevent or treat postpartum hypertension...
  4. pmc Ethics review as a component of institutional approval for a multicentre continuous quality improvement project: the investigator's perspective
    Hanna Ezzat
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, V6 H 3N1, Canada
    BMC Health Serv Res 10:223. 2010
    ..We used our experience with ethical review of The Canadian Perinatal Network (CPN), to gain insight into the Canadian system...
  5. ncbi request reprint The Control of Hypertension In Pregnancy Study pilot trial
    L A Magee
    Department of Medicine, University of British Columbia, Vancouver, Canada
    BJOG 114:770, e13-20. 2007
    ..To determine whether 'less tight' (versus 'tight') control of nonsevere hypertension results in a difference in diastolic blood pressure (dBP) between groups...
  6. ncbi request reprint Women's views of their experiences in the CHIPS (Control of Hypertension in Pregnancy Study) Pilot Trial
    L A Magee
    Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Hypertens Pregnancy 26:371-87. 2007
    ..We sought to compare women's views about their care in a randomized trial of 'less tight' vs. 'tight' control of non-proteinuric pre-existing or gestational hypertension in pregnancy...
  7. doi request reprint The management of severe hypertension
    Laura A Magee
    Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Semin Perinatol 33:138-42. 2009
    ..Most commonly, severe hypertension is treated with parenteral labetalol or hydralazine, or oral nifedipine (capsules or PA tablet). Other options will depend on local availability. MgSO(4) should not be relied on as an antihypertensive...
  8. ncbi request reprint The safety of antihypertensives for treatment of pregnancy hypertension
    L A Magee
    Department of Specialized Women s Health, BC Women s Hospital and Health Centre, 4500 Oak Street, Room IU59, Vancouver, BCV6H 3N1, Canada
    Expert Opin Drug Saf 3:25-38. 2004
    ..The treatment of severe hypertension is addressed separately from the treatment of mild-to-moderate hypertension, for which the maternal and fetal risks are substantially different...
  9. ncbi request reprint Control of hypertension in pregnancy
    Laura A Magee
    BC Women s Hospital and Health Centre and the Child and Family Research Institute, University of British Columbia, 4500 Oak Street, Room D213, Vancouver, BC V6H 3N1, Canada
    Curr Hypertens Rep 11:429-36. 2009
    ..The CHIPS Trial (Control of Hypertension In Pregnancy Study) is recruiting to answer this question...
  10. pmc Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis
    Laura A Magee
    University of British Columbia, BC Women s Hospital and Health Centre, 4500 Oak Street, Vancouver, BC, Canada V6H 3N1
    BMJ 327:955-60. 2003
    ..To review outcomes in randomised controlled trials comparing hydralazine against other antihypertensives for severe hypertension in pregnancy...
  11. ncbi request reprint Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia
    Laura A Magee
    Centre for Healthcare Innovation and Improvement, British Columbia Research Institute for Children s and Women s Health, Department of Specialized Women s Health, BC Women s Hospital and Health Centre, Canada
    Am J Obstet Gynecol 193:153-63. 2005
    ..Does the use of nifedipine and magnesium sulfate together increase serious magnesium-related effects?..
  12. ncbi request reprint Treating hypertension in women of child-bearing age and during pregnancy
    L A Magee
    Children s and Women s Health Centre of British Columbia, University of British Columbia, Vancouver, Canada
    Drug Saf 24:457-74. 2001
    ..Methyldopa and other beta-blockers have been used most extensively. Reporting bias and the uncertainty of outcomes as defined warrant cautious interpretation of these findings and preclude treatment recommendations...
  13. ncbi request reprint Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP)
    Laura A Magee
    Department of Specialized Women s Health, BC Women s Hospital and Health Centre, Vancouver, Canada
    Am J Obstet Gynecol 186:S256-61. 2002
    ..Our goal was to review the safety and effectiveness of available antiemetics for treatment of nausea and vomiting of pregnancy...
  14. ncbi request reprint Identifying potentially eligible subjects for research: paper-based logs versus the hospital administrative database
    L A Magee
    Department of Medicine, Child and Family Research Institute, Vancouver, British Columbia, Canada
    Chronic Dis Inj Can 32:43-6. 2011
    ..Women with one or more conditions most commonly associated with very pre-term birth are included if admitted to a participating tertiary perinatal unit at 22 weeks and 0 days to 28 weeks and 6 days...
  15. pmc How to manage hypertension in pregnancy effectively
    Laura A Magee
    BC Women s Hospital and Heath Centre and University of British Columbia, 4500 Oak Street, Room D213, Vancouver, BC V6H 3N1, Canada
    Br J Clin Pharmacol 72:394-401. 2011
    ..Oral labetalol and methyldopa are used most commonly, but many different β-adrenoceptor blockers and calcium channel blockers have been studied in clinical trials...
  16. doi request reprint Therapeutics and anaesthesia
    Laura A Magee
    Department of Medicine, University of British Columbia, Vancouver, Canada
    Best Pract Res Clin Obstet Gynaecol 25:477-90. 2011
    ..Finally, anaesthetists play a critical role in the management of women with a hypertension disorder of pregnancy, and should be involved earlier rather than later in the course of their care...
  17. doi request reprint Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission
    B Payne
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada
    BJOG 120:113-8. 2013
    ..8 (95% CI 9.1-24.1) or 17.5 (95% CI 11.7-26.3) based on 6- and 24-hour data, respectively, for the women identified to be at highest risk (predicted probability ≥ 30%)...
  18. ncbi request reprint Serious perinatal complications of non-proteinuric hypertension: an international, multicentre, retrospective cohort study
    L A Magee
    BC Women s Hospital and Health Centre, Vancouver, BC, Canada
    J Obstet Gynaecol Can 25:372-82. 2003
    ....
  19. doi request reprint Sildenafil citrate therapy for severe early-onset intrauterine growth restriction
    P von Dadelszen
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada
    BJOG 118:624-8. 2011
    ..3, 126; compared with institutional Sildenafil-naive early-onset IUGR controls]. Randomised controlled trial data are required to determine whether Sildenafil improves perinatal outcomes for early-onset IUGR-complicated pregnancies...
  20. ncbi request reprint Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes
    J Menzies
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada
    Hypertens Pregnancy 26:447-62. 2007
    ..To determine the association between adverse maternal/perinatal outcomes and Canadian and U.S. preeclampsia severity criteria...
  21. ncbi request reprint The generalizability of trial data; a comparison of beta-blocker trial participants with a prospective cohort of women taking beta-blockers in pregnancy
    L A Magee
    Department of Medicine, Mount Sinai Hospital, 600 University Avenue, Suite 428, Tornoto, Ontario M5G 1X5, Canada
    Eur J Obstet Gynecol Reprod Biol 94:205-10. 2001
    ..To evaluate the generalizability of randomized controlled trial (RCT) data to obstetric practice, using the example of beta-blocker therapy...
  22. ncbi request reprint Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics? A systematic review
    E J Waterman
    Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Hypertens Pregnancy 23:155-69. 2004
    ..To examine fetal (FHR) and neonatal heart rate patterns following use of common oral antihypertensives in pregnancy...
  23. doi request reprint Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial
    E Rey
    Division of Obstetrics Medicine, Department of Obstetrics and Gynaecology, CHU Sainte Justine, Montreal, QC, Canada
    J Thromb Haemost 7:58-64. 2009
    ..The role of anticoagulants for the prevention of placental-mediated pregnancy complications is uncertain...
  24. doi request reprint Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model
    Peter von Dadelszen
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada
    Lancet 377:219-27. 2011
    ..We developed and validated the fullPIERS model with the aim of identifying the risk of fatal or life-threatening complications in women with pre-eclampsia within 48 h of hospital admission for the disorder...
  25. doi request reprint Expectant management of severe preeclampsia remote from term: a structured systematic review
    L A Magee
    Departments of Medicine, University of British Columbia, Vancouver, BC, V6H 3N1, Canada
    Hypertens Pregnancy 28:312-47. 2009
    ..To compare outcomes associated with expectant vs. interventionist care of severe preeclampsia in observational studies...
  26. ncbi request reprint The complications of hypertension in pregnancy
    P von Dadelszen
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada
    Minerva Med 96:287-302. 2005
    ....
  27. ncbi request reprint Drugs in pregnancy. Antihypertensives
    L A Magee
    Department of Specialized Women's Health, BC Women's Hospital and Health Centre, University of British Columbia, Vancouver, BC, Canada
    Best Pract Res Clin Obstet Gynaecol 15:827-45. 2001
    ..Methodological problems with published trials warrant cautious interpretation of these findings. Methyldopa and beta-blockers have been used most extensively, although atenolol may impair fetal growth in particular and should be avoided...
  28. ncbi request reprint Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis
    Peter von Dadelszen
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC
    J Obstet Gynaecol Can 24:941-5. 2002
    ..To update our previous analysis of randomized controlled trials in pregnancy hypertension, which discerned that greater treatment-induced decreases in maternal mean arterial pressure (MAP) appear to adversely affect fetal growth...
  29. ncbi request reprint Levels of antibodies against cytomegalovirus and Chlamydophila pneumoniae are increased in early onset pre-eclampsia
    Peter von Dadelszen
    Department of Obstetrics and Gynaecology, Children s and Women s Health Centre of British Columbia, University of British Columbia, 2H30 4500 Oak Street, Vancouver, BC, Canada V6H 3N1
    BJOG 110:725-30. 2003
    ..Could reactivated chronic infection be both a trigger for these differential maternal responses to the same underlying pathology and a link between pre-eclampsia and its attendant lifelong risks of atherosclerosis?..
  30. doi request reprint The active implementation of pregnancy hypertension guidelines in British Columbia
    Peter von Dadelszen
    Departments of Obstetrics and Gynaecology, Anesthesiology, Pharmacology and Therapeutics, and Medicine, School of Public and Population Health, Child and Family Research Institute, and Faculty of Medicine, University of British Columbia, and the BC Perinatal Health Program, Vancouver, British Columbia, Canada
    Obstet Gynecol 116:659-66. 2010
    ..To reduce maternal and perinatal morbidity and mortality associated with the hypertensive disorders of pregnancy by using an active model of guideline implementation...
  31. ncbi request reprint Could an infectious trigger explain the differential maternal response to the shared placental pathology of preeclampsia and normotensive intrauterine growth restriction?
    Peter von Dadelszen
    Department of Obstetrics and Gynaecology, Children s and Women s Health Centre of British Columbia and University of British Columbia, Vancouver, British Columbia, Canada
    Acta Obstet Gynecol Scand 81:642-8. 2002
    ..Also reviewed is the human and animal model evidence for an infectious trigger for preeclampsia. Perhaps preeclampsia truly is the 'toxemia' of pregnancy...
  32. ncbi request reprint Subclassification of preeclampsia
    Peter von Dadelszen
    Department of Obstetrics and Gynaecology, Division of Maternal Fetal Medicine, University of British Columbia, Vancouver, Canada
    Hypertens Pregnancy 22:143-8. 2003
    ..We suggest that a first step would be to subdivide preeclampsia into early-onset disease (< 34 + 0 weeks') and late onset disease (> 34 + 0 weeks')...
  33. ncbi request reprint Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity?
    Peter von Dadelszen
    Department of Obstetrics and Gynaecology, Division of Maternal Fetal Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Crit Care Med 30:1883-92. 2002
    ..To determine which patients would be offered rhAPC, the literature pertaining to fetal/neonatal outcomes for preeclampsia remote from term, transplacental transport of protein C, and pregnancy experience with the compound were reviewed...
  34. doi request reprint Predicting adverse outcomes in women with severe pre-eclampsia
    Peter von Dadelszen
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada
    Semin Perinatol 33:152-7. 2009
    ....
  35. ncbi request reprint Antihypertensive medications in management of gestational hypertension-preeclampsia
    Peter von Dadelszen
    Centre for Healthcare Innovation and Improvement, and the Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada
    Clin Obstet Gynecol 48:441-59. 2005
  36. ncbi request reprint The prediction of adverse maternal outcomes in preeclampsia
    Peter von Dadelszen
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC
    J Obstet Gynaecol Can 26:871-9. 2004
    ....
  37. ncbi request reprint Evidence-based management for preeclampsia
    Peter von Dadelszen
    Department of Obstetrics and Gynaecology, University of British Columbia and British Columbia Reproductive Care Program, Provincial Health Services Authority, Vancouver, BC, Canada
    Front Biosci 12:2876-89. 2007
    ..11) Early-onset and/or severe preeclampsia predict later cardiovascular morbidity and mortality; it would seem prudent to offer such women screening and lipid lowering interventions...
  38. ncbi request reprint Instituting surveillance guidelines and adverse outcomes in preeclampsia
    Jennifer Menzies
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada
    Obstet Gynecol 110:121-7. 2007
    ..To assess the incidence of combined adverse maternal and perinatal outcomes in women with preeclampsia before and after introducing standardized assessment and surveillance...
  39. doi request reprint Toll-like receptors 2 and 4 and the cryopyrin inflammasome in normal pregnancy and pre-eclampsia
    F Xie
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada
    BJOG 117:99-108. 2010
    ....
  40. doi request reprint What is SNOMED CT and why should the ISSHP care?
    K A Massey
    UBC, Obstetrics and Gynaecology, Vancouver, British Columbia, Canada
    Hypertens Pregnancy 28:119-21. 2009
    ..We believe that members of the ISSHP, and others interested in the HDP, should take a leadership role in this regard for a number of reasons...
  41. doi request reprint Optimal timing of delivery in pregnancies with pre-existing hypertension
    J A Hutcheon
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada
    BJOG 118:49-54. 2011
    ....
  42. doi request reprint An association between cytomegalovirus infection and pre-eclampsia: a case-control study and data synthesis
    Fang Xie
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada
    Acta Obstet Gynecol Scand 89:1162-7. 2010
    ..Pre-eclampsia shares several similarities with atherosclerotic heart disease. We explored whether, like atherosclerosis, there is a potential link between cytomegalovirus (CMV) infection and pre-eclampsia...
  43. ncbi request reprint Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction
    D Goswami
    Department of Obstetrics and Gynaecology, University of British Columbia, 4500 Oak Street, Vancouver BC V6H 3N1, Canada
    Placenta 27:56-61. 2006
    ..Similar placental pathology occurs in some cases of normotensive intrauterine growth restriction (nIUGR), but in the absence of maternal disease...
  44. ncbi request reprint Neutrophil apoptosis in preeclampsia, do steroids confound the relationship?
    Akiko Fuchisawa
    Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia V6H 3N1, Canada
    J Obstet Gynaecol Res 30:342-8. 2004
    ..To investigate the influence of maternal corticosteroid administration on neutrophil apoptosis in early onset preeclampsia...
  45. ncbi request reprint Development of a health-related quality of life instrument for nausea and vomiting of pregnancy
    Laura A Magee
    University of Toronto, Department of Medicine, Mount Sinai Hospital, The Motherisk Program, Vancouver, British Columbia, Canada
    Am J Obstet Gynecol 186:S232-8. 2002
    ..To develop a questionnaire that measures change in symptoms of nausea and vomiting of pregnancy (NVP)...
  46. ncbi request reprint Nifedipine for severe hypertension in pregnancy: emotion or evidence?
    Laura A Magee
    Department of Specialized Women s Health, BC Women s Hospital and Health Centre, Vancouver, British Columbia, Canada
    J Obstet Gynaecol Can 27:260-2. 2005
    ..We must resist the temptation to throw out of our limited therapeutic armamentarium an effective oral preparation before adequately considering the evidence...
  47. ncbi request reprint Preeclampsia and future cardiovascular risk
    J Newstead
    University of Saskatchewan, Department of Medicine, Saskatoon, SK, Canada
    Expert Rev Cardiovasc Ther 5:283-94. 2007
    ....
  48. pmc Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review
    Anne Marie Côté
    BC Women s Hospital and Health Centre, Vancouver, BC, Canada
    BMJ 336:1003-6. 2008
    ..To review the spot protein:creatinine ratio and albumin:creatinine ratio as diagnostic tests for significant proteinuria in hypertensive pregnant women...
  49. ncbi request reprint Our patients do not need endocarditis prophylaxis for genitourinary tract procedures: insights from the 2007 American Heart Association guidelines
    Eliana Castillo
    Department of Medicine, University of British Columbia, Vancouver, BC
    J Obstet Gynaecol Can 30:796-9. 2008
    ..A short discussion on enterococcal infections associated to obstetric and gynaecological procedures and therapeutic implications is presented...
  50. ncbi request reprint Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis
    Shekoufeh Nikfar
    The Motherisk Program, Hospital for Sick Children, Toronto, Ontario, Canada
    Dig Dis Sci 47:1526-9. 2002
    ..72-1.94. In conclusion, proton pump inhibitors do not present a major teratogenic risk when used in recommend doses. These data are reassuring for the countless patients who have used these agents in the early part of their pregnancies...
  51. ncbi request reprint A survey of Canadian practitioners regarding the management of the hypertensive disorders of pregnancy
    M Caetano
    Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Canada
    Hypertens Pregnancy 23:61-74. 2004
    ..How Canadian practitioners are managing the hypertensive disorders of pregnancy (HDP) is not known, particularly in relation to the 1997 guidelines published by the Canadian Hypertension Society (CHS)...
  52. ncbi request reprint A survey of canadian practitioners regarding diagnosis and evaluation of the hypertensive disorders of pregnancy
    M Caetano
    Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Canada
    Hypertens Pregnancy 23:197-209. 2004
    ..How Canadian practitioners are diagnosing and managing the hypertensive disorders of pregnancy (HDP), particularly in relation to the 1997 recommendations published by the Canadian Hypertension Society (CHS), is not known...
  53. ncbi request reprint The safety of oral hypoglycemic agents in the first trimester of pregnancy: a meta-analysis
    Sheryl J Gutzin
    Department of Medicine, Mount Sinai Hospital and University of Toronto
    Can J Clin Pharmacol 10:179-83. 2003
    ..To examine the relationship between first-trimester exposure to oral hypoglycemic agents (OHAs), congenital anomalies and neonatal mortality, accounting for the potential confounding effect of maternal glycemic control...